Results

1–10 of 12 results for Complement

Inhibition of C1q Protects Photoreceptor Synapses in a Light Damage Model and Is a Potential Treatment for Geographic Atrophy
Patrick Dewey Williams, MD
Annual Meeting Talks
2022
Association Between Dysfunctional Complement Factor I: Rare Variant Status and Progression to Advanced AMD Outcomes
Johanna M. Seddon, MD, ScM, FARVO, FASRS
Annual Meeting Talks
2022
Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022
Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Utilizing Novel Sialic Acid-Coated Nanoparticles
Robert L. Avery, MD
Updates from the Field
2024
Beyond Complement: A Novel FAS Inhibition Approach for Neuroprotection in GA
Vaidehi S. Dedania, MD
Updates from the Field
2024
Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, and GATHER1 Study: Results From a Post-Hoc Analysis of Nascent Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2021
Assessment of Progression of Geographic Atrophy in the FILLY Study
David R Lally, MD
On Demand Cases, Courses, and Papers
2020
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2020